Cover Image
市場調查報告書

高膽固醇症治療藥的全球市場:2016∼2020年

Global Hypercholesterolemia Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 364963
出版日期 內容資訊 英文 98 Pages
訂單完成後即時交付
價格
Back to Top
高膽固醇症治療藥的全球市場:2016∼2020年 Global Hypercholesterolemia Drugs Market 2016-2020
出版日期: 2016年07月25日 內容資訊: 英文 98 Pages
簡介

高膽固醇症,特徵是血中的整體膽固醇和LDL-C值高,成為中風和動脈粥狀硬化等冠狀動脈疾病的原因。全球高膽固醇症治療藥市場,預計2016∼2020年以CA6.78%擴大。

本報告提供全球高膽固醇症治療藥市場相關調查,市場成長預測,各地區趨勢,市場趨勢與課題,主要供應商的競爭趨勢等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 高膽固醇症:概要

  • 高膽固醇症的歷史
  • 高膽固醇症管理市場趨勢
  • 高膽固醇症的處方環境
  • 高膽固醇症的管理
  • 流行病學
  • 未滿足需求和PCSK9和CETP抑制劑所扮演的角色

第6章 產品研發線

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 高膽固醇症治療藥的全球市場:各疾病分類

  • FH
  • 非FH

第9章 高膽固醇症治療藥的全球市場:各作用機制市場分類

  • HMG-CoA還原酶抑制劑
  • 纖維蛋白酸衍生物
  • 菸酸
  • 膽汁抑製藥
  • 其他

第10章 高膽固醇症治療藥的全球市場:各類藥物市場分類

  • Statin
  • 非Statin

第11章 高膽固醇症治療藥的全球市場:各地區分類

  • 各地區分類
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第12章 高膽固醇症治療藥的全球市場:促進要素

  • 冠狀動脈疾病的風險增加
  • 慢性疾病的罹患率上升
  • 有潛力的藥劑開發平台
  • 高膽固醇症的管理的ATP指南的變更
  • 老年人的增加

第13章 促進要素的影響

第14章 高膽固醇症治療藥的全球市場:課題

  • 品牌藥的專利壟斷性的喪失
  • 目前治療方法相關缺點
  • 高額的治療費
  • 嚴厲的法律規章指南
  • 恰當的診斷不足

第15章 促進要素與課題的影響

第16章 高膽固醇症治療藥的全球市場:趨勢

第17章 供應商環境

  • 競爭模式
  • 市場佔有率分析:2015年

第18章 主要供應商簡介

  • AbbVie
  • Aegerion Pharmaceuticals
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • 其他值得注意的供應商

第19章 附錄

第20章 關於Technavio

目錄
Product Code: IRTNTR9069

About Hypercholesterolemia

Hypercholesterolemia is characterized by high levels of total cholesterol and LDL-C in the blood. High cholesterol levels can cause CVDs such as stroke and atherosclerosis. The typical range of total blood cholesterol is 140-200 mg/dL.Blood cholesterol contains individual components such as LDL-C and HDL-C. LDL carries cholesterol to the body and HDL removes cholesterol from the cells by reversing cholesterol transport to the liver.

Technavio's analysts forecast the global hypercholesterolemia drugs market to decline at a CAGR of 6.78% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global hypercholesterolemia drugs market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generics, and off-label drugs used to treat hypercholesterolemia.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Hypercholesterolemia Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • AbbVie
  • Aegerion Pharmaceuticals
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi

Other Prominent Vendors

  • Alnylam Pharmaceuticals
  • Amarin
  • Amgen
  • AtheroNova
  • Aurobindo Pharma
  • Biocon
  • Biospherics
  • Bristol-Myers Squibb
  • Catabasis Pharmaceuticals
  • Cerenis Therapeutics
  • Cipla
  • CJ HealthCare
  • CKD Bio
  • Concord Biotech
  • CymaBay Therapeutics
  • Daewoong Pharmaceutical
  • Daiichi Sankyo
  • Eli Lilly
  • Esperion Therapeutics
  • GlaxoSmithKline
  • HanAll BioPharma
  • JW Pharmaceuticals
  • Kadmon Pharmaceuticals
  • Kowa Company
  • Laboratoires
  • Livzon Pharmaceutical
  • Lupin Pharmaceuticals
  • Madrigal Pharmaceuticals
  • Merz Pharmaceuticals
  • Mylan
  • Novartis
  • Regeneron Pharmaceuticals
  • ReGenX Biosciences
  • Santaris Pharma
  • Serometrix
  • Sun Pharmaceutical
  • Arbutus Biopharma
  • Teva Pharmaceuticals
  • Torrent Pharmaceuticals
  • Zydus Cadila

Market driver

  • Rising prevalence of chronic diseases
  • For a full, detailed list, view our report

Market challenge

  • Loss of patent exclusivity of branded therapies
  • For a full, detailed list, view our report

Market trend

  • Expected entry of cost-effective OTC versions
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings
  • Drug profiles

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Clinical application
  • Treatment guidelines
  • Key buying criteria

PART 05: Hypercholesterolemia: An overview

  • History of hypercholesterolemia
  • Hypercholesterolemia management market dynamics
  • Hypercholesterolemia prescription landscape
  • Management of hypercholesterolemia
  • Epidemiology
  • Unmet medical needs and role of PCSK9 and CETP inhibitors

PART 06: Pipeline portfolio

  • Information on pipeline candidates

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Segmentation by type of disease

  • FH
  • Non-FH

PART 09: Market segmentation by MOA

  • HMG-CoA reductase inhibitors
  • Fibric acid derivatives
  • Nicotinic acid
  • Bile acid sequestrants
  • Other

PART 10: Market segmentation by drug class

  • Statins
  • Non-statins

PART 11: Geographical segmentation

  • Global hypercholesterolemia drugs market by geographical segmentation 2015-2020
  • Hypercholesterolemia drugs market in Americas
  • Hypercholesterolemia drugs market in EMEA
  • Hypercholesterolemia drugs market in APAC

PART 12: Market drivers

  • Increasing risk of CVDs
  • Rising prevalence of chronic diseases
  • Promising pipeline of drugs
  • Change in ATP guidelines for management of hypercholesterolemia
  • Growing older population

PART 13: Impact of drivers

PART 14: Market challenges

  • Loss of patent exclusivity of branded therapies
  • Drawbacks associated with current therapies
  • High cost of therapy
  • Stringent regulatory guidelines
  • Lack of proper diagnosis

PART 15: Impact of drivers and challenges

PART 16: Market trends

  • Expected entry of cost-effective OTC versions
  • Increasing use of statins
  • Increased use of combination therapies
  • Consideration of lifestyle management in ATP guidelines

PART 17: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015

PART 18: Key vendor analysis

  • AbbVie
  • Aegerion Pharmaceuticals
  • AstraZeneca
  • Merck
  • Pfizer
  • Sanofi
  • Other prominent vendors

PART 19: Appendix

  • List of abbreviations

PART 20: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Different class of lipoproteins
  • Exhibit 03: Evaluation of lipoprotein levels based on ATP III classification
  • Exhibit 04: Key buying criteria for hypercholesterolemia drugs
  • Exhibit 05: Timeline of cholesterol lowering drugs
  • Exhibit 06: Market dynamics for hypercholesterolemia
  • Exhibit 07: Prescription landscape for statins 2015
  • Exhibit 08: Prescription landscape for ezetimibe 2015
  • Exhibit 09: Prescription landscape for other classes 2015
  • Exhibit 10: Distribution of cholesterol-lowering medication for individuals above 40 years
  • Exhibit 11: Percentage use of prescription cholesterol-lowering medication in US for various indications 2015
  • Exhibit 12: Treatment of hypercholesterolemia
  • Exhibit 13: Pharmacological treatment of hypercholesterolemia
  • Exhibit 14: High cholesterol levels by race and ethnicity in US 2015
  • Exhibit 15: PCSK9 inhibitors in preclinical and clinical development 2015
  • Exhibit 16: Pipeline portfolio: Global hypercholesterolemia drugs market
  • Exhibit 17: Pipeline share of hypercholesterolemia drugs
  • Exhibit 18: Global hypercholesterolemia drugs market 2015-2020 ($ billions)
  • Exhibit 19: Five forces analysis
  • Exhibit 20: Classification of hyperlipidemia
  • Exhibit 21: Global hypercholesterolemia market segmentation by MOA
  • Exhibit 22: Global hypercholesterolemia market segmentation by MoA 2015
  • Exhibit 23: Global hypercholesterolemia drugs market segmentation by drug class
  • Exhibit 24: Global hypercholesterolemia drugs market by drug class 2015 (% share)
  • Exhibit 25: Hypercholesterolemia drugs market revenue by drug class 2015-2020 ($ billions)
  • Exhibit 26: Global statin market 2015-2020 ($ billions)
  • Exhibit 27: Number of prescriptions for statins in US
  • Exhibit 28: Usage of statins for hypercholesterolemia in US 2015
  • Exhibit 29: Usage of statins for hypercholesterolemia in UK 2015
  • Exhibit 30: Global non-statins market 2015-2020 ($ billions)
  • Exhibit 31: Number of prescriptions for non-statins in US
  • Exhibit 32: Global hypercholesterolemia drugs market: YoY growth and revenue based on drug class 2015-2020
  • Exhibit 33: Segmentation of global hypercholesterolemia drugs markets by geography 2015
  • Exhibit 34: Hypercholesterolemia drugs market revenue by geography 2015-2020 ($ billions)
  • Exhibit 35: Percentage share of hypercholesterolemia drugs market by geography 2015-2020 (%)
  • Exhibit 36: Hypercholesterolemia drugs market in Americas 2015-2020 ($ billions)
  • Exhibit 37: Share of hypercholesterolemia drugs market in Americas by country 2015
  • Exhibit 38: Hypercholesterolemia drugs market in EMEA 2015-2020 ($ billions)
  • Exhibit 39: Hypercholesterolemia drugs market in APAC 2015-2020 ($ billions)
  • Exhibit 40: Global hypercholesterolemia drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 41: Population aged 60 years and over: World, developed and developing regions ($ millions)
  • Exhibit 42: Impact of drivers
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Arguments for and against OTC switch by pharmaceutical companies and regulatory organizations
  • Exhibit 45: Market share analysis of global hypercholesterolemia drugs market 2015
  • Exhibit 46: Revenue from the sales of top five products in hypercholesterolemia drugs market 2013-2015 ($ billions)
  • Exhibit 47: AbbVie: YoY revenue and growth rate of lipid franchise portfolio 2013-2015 ($ millions)
  • Exhibit 48: Key takeaways
  • Exhibit 49: Aegerion: YoY revenue and growth rate of JUXTAPID 2013-2015 ($ millions)
  • Exhibit 50: Key takeaways
  • Exhibit 51: AstraZeneca: YoY revenue and growth rate of Crestor 2013-2015 ($ billions)
  • Exhibit 52: AstraZeneca: Geographic segmentation of Crestor 2015 by revenue
  • Exhibit 53: Key takeaways
  • Exhibit 54: Merck: YoY revenue and growth rate of Zetia 2013-2015 ($ billions)
  • Exhibit 55: Merck: YoY revenue and growth rate of Vytorin 2013-2015 ($ billions)
  • Exhibit 56: Merck: YoY revenue and growth rate of Zocor 2013-2015 ($ millions)
  • Exhibit 57: Merck: Key takeaways
  • Exhibit 58: Pfizer: YoY revenue and growth rate of Lipitor 2013-2015 ($ billions)
  • Exhibit 59: Pfizer: Geographic segmentation of Lipitor by revenue 2015
  • Exhibit 60: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions)
  • Exhibit 61: Key takeaways
  • Exhibit 62: Sanofi: Key takeaways
Back to Top